Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
4.6 Metabolism Plasma, bile, urine, and fecal samples of intact SD rats or BDC rats after a single administration of [3H]BPC157 were analyzed by HPLC combined with a low-energy radionuclide detection technique to obtain the radiometabolite profiles of [3H]BPC157
Phase 2 (NEJM, 2023, n=338, 48 weeks): up to 24.2% average body-weight loss on the 12mg dose
Severe abdominal pain, blood in stools, or persistent vomiting require prompt medical attention pancreatitis and gallbladder disease are recognised class-related risks
Highly pure, patented active ingredient
US$ 21.71
US$ 28.59
US$ 26.18
US$ 23.90
US$ 27.10
